research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
Search
for
Sort by
Research
60-90 / 1000+ results research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
5-Alpha-Reductase Inhibitors can cause negative side effects.
research Re: Inhibitors of 5α-Reductase-Related Side Effects in Patients Seeking Medical Care for Sexual Dysfunction
research Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
The new compound may be a safer alternative to finasteride for prostate protection.
research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Finasteride: the first 5 alpha-reductase inhibitor.
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/research/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID ‐19 pandemic?
5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research Screen steroid 5 alpha-reductase inhibitors in vitro by high performance liquid chromatography
The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
research The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
research New 5?-reductase inhibitors: In vitro and in vivo effects
Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
research PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
research 胃切除・腸切除術後の退院指導-パンフレットを使用して-
Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
research The clinical applications of five-alpha reductase inhibitors.
Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
research In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5α-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole
Ketoconazole increases finasteride's effectiveness and lifespan in the body.
research Five-alpha-reductase Inhibitors for prostate cancer prevention.
5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.